U.S. biotech company Genzyme Inc. (GENZ) rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA (SNY) on Monday, setting the stage for a protracted and potentially hostile takeover battle. – Reuters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.